RE-BVS – Piemonte Repository

Sfoglia per AUTORE
GELSOMINO F
Collezione AOU Città della Salute di Torino

Items : 8

Impact of edoxaban-related adverse events in patients with cancer experiencing venous thromboembolism during antineoplastic therapy: Results of the phase IV EDOI study (GOIRC-05-2018). in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2025 Mar 26;219:115296. doi: 10.1016/j.ejca.2025.115296. Epub 2025 Feb 9.

2025
AOU Città della Salute di Torino

Maglietta G; Damato A; Finotto S; Mandarà M; Tamberi S; Grisanti S; Brighenti M; Tiseo M; Montesarchio V; Catino A; Gelsomino F; Giovanardi F; Antonuzzo L; Romagnani A; Gervasi E; Di Maio M; Pinto C;

Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE Study. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2024 Aug 1;42(22):2637-2644. doi: 10.1200/JCO.23.02728. Epub 2024 Jun 12.

2024
AOU Città della Salute di Torino

Antoniotti C; Rossini D; Pietrantonio F; Salvatore L; Lonardi S; Tamberi S; Marmorino F; Moretto R; Prisciandaro M; Tamburini E; Tortora G; Passardi A; Bergamo F; Raimondi A; Ritorto G; Borelli B; Conca V; Ugolini C; Aprile G; Antonuzzo L; Gelsomino F; Martinelli E; Pella N; Masi G; Boni L; Galon J; Cremolini C;

Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort Study. in Cancers / Cancers (Basel). 2022 Nov 9;14(22):5513. doi: 10.3390/cancers14225513.

2022
ASL Torino 4
AOU Città della Salute di Torino

Garrone O; Facciorusso A; Memeo R; de Angelis N; Germini A; Gjoni E; Roberto M; De Tursi M; Morelli C; Berardi R; Giampieri R; Depetris I; Zurlo IV; Gelsomino F; Nigro O; Filippi R; Salvatore L; Bonomi A; Cotsoglou C; Granieri S; Ramai D; Ghidini M; Parisi A;

A multicenter study of skin toxicity management in patients with left-sided, RAS/BRAF wild-type metastatic colorectal cancer treated with first-line anti-EGFR-based doublet regimen: is there room for improvement? in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer / Support Care Cancer. 2022 Mar;30(3):2455-2465. doi: 10.1007/s00520-021-06652-5. Epub 2021 Nov 15.

2022
ASL Torino 4
AOU Città della Salute di Torino

Ferri C; Parisi A; Ficorella C; Cortellini A; Pensieri MV; Aimar G; Roberto M; Petrillo A; Zoratto F; Spinelli GP; Garajova I; Vitale P; Zanaletti N; De Tursi M; Di Pietro FR; Morelli C; Giampieri R; Depetris I; Keränen SR; Lombardi P; Zurlo IV; Dell'Aquila E; Gelsomino F; Ghidini M; Nigro O; Filippi R; Salvatore L; Porzio G; Fargnoli MC; et alii...

Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial. in The Lancet. Oncology / Lancet Oncol. 2022 Jul;23(7):876-887. doi: 10.1016/S1470-2045(22)00274-1. Epub 2022 May 27.

2022
AOU Città della Salute di Torino

Antoniotti C; Rossini D; Pietrantonio F; Catteau A; Salvatore L; Lonardi S; Boquet I; Tamberi S; Marmorino F; Moretto R; Ambrosini M; Tamburini E; Tortora G; Passardi A; Bergamo F; Kassambara A; Sbarrato T; Morano F; Ritorto G; Borelli B; Boccaccino A; Conca V; Giordano M; Ugolini C; Fieschi J; Papadopulos A; Massoué C; Aprile G; Antonuzzo L; et alii...

Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study. in Journal of clinical medicine / J Clin Med. 2022 Jan 28;11(3):713. doi: 10.3390/jcm11030713.

2022
AOU Città della Salute di Torino

Ricci AD; Pusceddu S; Panzuto F; Gelsomino F; Massironi S; De Angelis CG; Modica R; Ricco G; Torchio M; Rinzivillo M; Prinzi N; Rizzi F; Lamberti G; Campana D;

Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study. in Clinical colorectal cancer / Clin Colorectal Cancer. 2021 Dec;20(4):318-325. doi: 10.1016/j.clcc.2021.07.003. Epub 2021 Jul 18.

2021
ASL Torino 4
AOU Città della Salute di Torino

D'Orazio C; Ficorella C; Petrillo A; Ierino D; Spinelli GP; Roberto M; Zoratto F; Ghidini M; Vitale P; Garajova I; Troiani T; Di Pietro FR; De Galitiis F; Zanaletti N; Tinari N; Morelli C; Giampieri R; De Tursi M; Aimar G; Depetris I; Lombardi P; Keränen SR; Claudia F; Leo S; Dell'Aquila E; Spallanzani A; Zurlo V; Gelsomino F; Nigro O; et alii...

Post-Induction Management in Patients With Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Treated With First-Line Anti-EGFR-Based Doublet Regimens: A Multicentre Study. in Frontiers in oncology / Front Oncol. 2021 Oct 27;11:712053. doi: 10.3389/fonc.2021.712053. eCollection 2021.

2021
ASL Torino 4
AOU Città della Salute di Torino

Porzio G; Ficorella C; Ferri C; D'Orazio C; Patruno L; Petrillo A; Aimar G; Zoratto F; Roberto M; Spinelli GP; Garajova I; Vitale P; Zanaletti N; Morelli C; Di Marino P; Di Pietro FR; Depetris I; Giampieri R; Roselló Keränen S; Fulgenzi C; Lombardi P; Zurlo IV; Gelsomino F; Nigro O; Ghidini M; Tortora G; Salvatore L; Filippi R; Venditti O; et alii...